Roche announced a successful phase 3 trial for its oral selective estrogen receptor degrader (SERD) in a broad breast cancer patient population. The drug outperformed standard of care, marking a key step toward regulatory submissions and potential market entry. This victory follows earlier challenges and reaffirms Roche's commitment to developing innovative therapies in oncology. The outcome signals a promising new oral hormonal treatment option for breast cancer patients.